According to the Zhitong Finance App, Hanson Pharmaceuticals (03692.HK) announced that the B7-H3 targeted antibody-drug conjugate (ADC) HS20093, which was independently developed by the group, reached the main end of overall survival (OS) in critical phase III clinical trials (ARTEMIS-008) for patients with small cell lung cancer (SCLC) that progressed or recurred after platinum-containing treatment. When analyzed in the pre-set period, compared with topotecan, HS-20093 showed statistically significant and clinically significant improvements in OS, and consistent benefits were also observed at secondary clinical endpoints, including progression-free survival (PFS). The safety characteristics are consistent with the results of previous studies, and no new safety signals were found.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.